Literature DB >> 29254592

Comparison of different treatment planning optimization methods for vaginal HDR brachytherapy with multichannel applicators: A reduction of the high doses to the vaginal mucosa is possible.

Mauro Carrara1, Davide Cusumano2, Tommaso Giandini3, Chiara Tenconi3, Ester Mazzarella3, Simone Grisotto3, Eleonora Massari3, Davide Mazzeo3, Annamaria Cerrotta4, Brigida Pappalardi4, Carlo Fallai4, Emanuele Pignoli3.   

Abstract

PURPOSE: A direct planning approach with multi-channel vaginal cylinders (MVCs) used for HDR brachytherapy of vaginal cancers is particularly challenging. Purpose of this study was to compare the dosimetric performances of different forward and inverse methods used for the optimization of MVC-based vaginal treatments for endometrial cancer, with a particular attention to the definition of strategies useful to limit the high doses to the vaginal mucosa.
METHODS: Twelve postoperative vaginal HDR brachytherapy treatments performed with MVCs were considered. Plans were retrospectively optimized with three different methods: Dose Point Optimization followed by Graphical Optimization (DPO + GrO), Inverse Planning Simulated Annealing with two different class solutions as starting conditions (surflPSA and homogIPSA) and Hybrid Inverse Planning Optimization (HIPO). Several dosimetric parameters related to target coverage, hot spot extensions and sparing of organs at risk were analyzed to evaluate the quality of the achieved treatment plans. Dose homogeneity index (DHI), conformal index (COIN) and a further parameter quantifying the proportion of the central catheter loading with respect to the overall loading (i.e., the central catheter loading index: CCLI) were also quantified.
RESULTS: The achieved PTV coverage parameters were highly correlated with each other but uncorrelated with the hot spot quantifiers. HomogIPSA and HIPO achieved higher DHIs and CCLIs and lower volumes of high doses than DPO + GrO and surflPSA.
CONCLUSIONS: Within the investigated optimization methods, HIPO and homoglPSA showed the highest dose homogeneity to the target. In particular, homogIPSA resulted also the most effective in reducing hot spots to the vaginal mucosa.
Copyright © 2017 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HDR brachytherapy; HIPO; IPSA; Multichannel applicator; Vaginal cancer

Mesh:

Year:  2017        PMID: 29254592     DOI: 10.1016/j.ejmp.2017.11.007

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  5 in total

1.  Incorporating Treatment Time into Butterfly Optimization to Reduce Total Treatment Time for Vaginal Cylinder Brachytherapy.

Authors:  Xingen Wu; Ivan A Brezovich; Sui Shen; Elizabeth Covington; Dennis Stanley; Richard Popple
Journal:  Cureus       Date:  2022-04-06

2.  Dosimetric comparison of manual forward planning with uniform dwell times versus volume-based inverse planning in interstitial brachytherapy of cervical malignancies.

Authors:  Siddanna R Palled; Nikhila K Radhakrishna; Senthil Manikantan; Hashmath Khanum; Bindu K Venugopal; Lokesh Vishwanath
Journal:  Rep Pract Oncol Radiother       Date:  2020-09-11

3.  Dose Optimization for Single-Channel Vaginal Cylinder High-Dose-Rate Brachytherapy: A Double Prescription Method for Patients With Endometrial Adenocarcinoma.

Authors:  Xingen Wu; Andrew McDonald; Sui Shen; Dennis Stanley; Richard Popple; Samuel Marcrom; Robert Kim
Journal:  Cureus       Date:  2022-06-24

4.  Does inverse planning improve plan quality in interstitial high-dose-rate breast brachytherapy?

Authors:  Tibor Major; Georgina Fröhlich; Norbert Mészáros; Viktor Smanykó; Csaba Polgár
Journal:  J Contemp Brachytherapy       Date:  2020-04-30

5.  Comparison of two inverse planning algorithms for cervical cancer brachytherapy.

Authors:  Qi Fu; Yingjie Xu; Jing Zuo; Jusheng An; Manni Huang; Xi Yang; Jiayun Chen; Hui Yan; Jianrong Dai
Journal:  J Appl Clin Med Phys       Date:  2021-02-24       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.